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Aim To determine if red cell distribution width (RDW) is as-
sociated with all-cause mortality in patients on chronic di-
alysis and to evaluate its prognostic value among validated 
prognostic biomarkers.
Methods This is a single center, prospective longitudinal 
study. At the time of inclusion in January 2011, all patients 
were physically examined and a routine blood analysis was 
performed. A sera sample was preserved for determination 
of NT-pro-brain natriuretic peptide (NT-pro-BNP) and eo-
sinophil cationic protein. Carotid intima media thickness 
(IMT) was also measured. Following one year, all-cause 
mortality was evaluated.
Results Of 100 patients, 25 patients died during the fol-
low-up period of one-year. Patients who died had signifi-
cantly higher median [range] RDW levels (16.7% [14.3-19.5] 
vs 15.5% [13.2-19.7], P < 0.001. They had significantly higher 
Eastern Cooperative Oncology Group (ECOG) performance 
status (4 [2-4] vs 2 [1-4], P < 0.001), increased intima-media 
thickness (IMT) (0.71 [0.47-1.25] vs 0.63 [0.31-1.55], P = 0.011), 
increased NT-pro-BNP levels (8300 [1108-35000] vs 4837 
[413-35000], P = 0.043), and increased C-reactive protein 
(CRP) levels (11.6 [1.3-154.2] vs 4.9 [0.4-92.9], P < 0.001). For 
each 1% point increase in RDW level as a continuous vari-
able, one-year all cause mortality risk was increased by 54% 
in univariate Cox proportional hazard analysis. In the final 
model, when RDW was entered as a categorical variable, 
mortality risk was significantly increased (hazard ratio, 5.15, 
95% confidence interval, 2.33 to 11.36) and patients with 
RDW levels above 15.75% had significantly shorter survival 
time (Log rank P < 0.001) than others.
Conclusions RDW could be an additive predictor for all-
cause mortality in patients on chronic dialysis. Further-
more, RDW combined with sound clinical judgment im-
proves identification of patients who are at increased risk 
compared to RDW alone.
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In patients on chronic dialysis, the prevalence of cardiovas-
cular disease is very high, and among patients with chron-
ic renal failure atherosclerosis and cardiovascular diseases 
are the leading cause of morbidity and mortality (1,2). Re-
cent investigations of atherosclerosis have focused on in-
flammation, emphasizing the importance of endothelial 
dysfunction and inflammatory biomarkers interaction, sug-
gesting that a biomarker such as C-reactive protein plays 
a key role in promoting atherosclerosis process and en-
dothelial cell activation and inflammation (3,4). C-reactive 
protein and NT-pro-brain natriuretic peptide (NT-pro-BNP) 
are strong and validated prognostic biomarkers, which are 
considered as gold standard in patient risk assessment and 
survival analysis (5). Also, recent studies have identified eo-
sinophilic cationic protein (ECP) as a biomarker of coronary 
atherosclerosis (6). It has been stated that ECP serum con-
centration is proportional to the growth of atherosclerotic 
plaque in the coronary vessels (6).
Several studies have identified red blood cell distribu-
tion width (RDW) as a strong and independent predictor 
of morbidity and mortality in general population (7,8), as 
well in different groups of patients with morbidities such 
as acute or chronic heart failure, cardiac arrest, pulmonary 
embolism, acute coronary syndrome, and even community 
acquired pneumonia (9-13). Furthermore, RDW has been 
identified as independent short- and long-term prognos-
tic marker in intensive care unit patients, which significantly 
improves risk stratification of simplified acute physiology 
score (SAPS) (14). It is defined as a measure of variability in 
size of circulation erythrocytes and has traditionally played 
a role in the differential diagnosis of anemia (10). In every-
day clinical practice, it is an automatically measured index, 
which is calculated by dividing standard deviation (SD) of 
red blood cells volume by mean corpuscular volume (MCV) 
and multiplying by 100 to express the results as percentage 
(10,15). Recently, it has been demonstrated that RDW could 
be an additive predictor for all-cause mortality in patients 
with acute renal failure treated with continuous renal re-
placement therapy (16). However, there are no data among 
patients with chronic renal failure treated with mainte-
nance dialysis. Therefore, we aimed to investigate whether 
RDW was associated with all-cause mortality in patients on 
chronic dialysis and whether it would provide meaningful 
prognostic value among validated prognostic biomarkers.
MethodS
Patients
This prospective longitudinal study was conducted in 
a hemodialysis department of a single tertiary aca-
demic hospital with approximately 115 patients on chron-
ic hemodialysis who were screened for participation. All 
patients with chronic renal failure who were treated with 
maintenance hemodialysis at the dialysis unit (Depart-
ment for Hemodialysis, University Hospital Dubrava) be-
tween December 2010 and January 2011, and who had 
been on hemodialysis for at least one year, were eligible for 
inclusion. Exclusion criteria were malignant disease, auto-
immune disease, chronic immunosuppressive treatment, 
or recent surgical procedure. Finally in January 2011, 100 
patients were included in the study cohort. All included 
individuals underwent detailed general examination with 
cardiovascular priority and were given a simple question-
naire (supplementary questionnaire) for evaluation of tra-
ditional risk factors. Body-mass index (BMI) was defined as 
weight (kg) per body surface (m2). Influence of dialysis was 
expressed as duration of dialysis in months and its perfor-
mance as outcome Kt/V (K – dialyzer clearance of urea × t 
– dialysis time/V – volume of distribution of urea, approxi-
mately equal to patient’s total body water), which was cal-
culated by the Daugirdas method, based on the reduc-
tion in the serum urea concentration during dialysis (17). 
Patients’ daily living abilities were graded according to 
Eastern Cooperative Oncology Group performance status 
(ECOG) (18) ranging from 0-5, with 0 indicating that the pa-
tient is fully active and capable for everyday normal activity 
and 5 indicating that he or she is dead (18). The intima-me-
dia thickness (IMT) of both carotid arteries was measured 
ultrasonographically with an Aloka 5500 Prosound ma-
chine (Hitachi Aloka, Tokyo, Japan) using a 7.5 MHz high-
resolution probe. IMT was defined according to the Man-
nheim Carotid Intima-Media Thickness Consensus (19). The 
patient follow-up was performed by means of telephone 
calls and personal interviews. The study was approved by 
the local ethics committee and all patients gave informed 
consent. The studied end-point was all-cause mortality. We 
would like to emphasize that all patients included in the 
study were treated in accordance with standardized proto-
cols for their disease/condition and that their inclusion in 
this study had no effect on their treatment, care provided, 
or the final outcome.
Laboratory assessment
Complete blood count (CBC) (including RDW calculation) 
was determined from whole blood with K2EDTA as an an-
ticoagulant on Advia 2120i analyzer (Siemens Healthcare 
Diagnostics, Tarrytown, NY, USA). The reference range of 
RDW for normal population in our laboratory is between 
9%-15%, but we used the median value because our analy-
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sis was performed in dialysis population, which is different 
from normal population. The concentrations of ECP, NT-pro-
BNP, high sensitive C-reactive protein (hs-CRP), creatinine, 
albumin, total cholesterol, iron, and unsaturated iron bind-
ing capacity (UIBC) were determined in the sera samples 
collected from all the participants. The sera were obtained 
after centrifugation at 1370 × g for 15 minutes in a 35 R Ro-
tina Hettich centrifuge (Tuttlingen, Germany), and then 
stored at -80°C until analysis. ECP was measured using flu-
oroimmunoassay method on Phadia 100 analyzer (Phadia 
AB, Uppsala, Sweden). The method includes the reaction of 
anti-ECP covalently coupled to ImmunoCAP with the ECP 
in the patient sample. After washing, enzyme labeled an-
tibodies to ECP were added to form a complex, and after 
incubation, the bound complex was incubated with a de-
veloping agent. The measured fluorescence of the eluate 
was proportional to the ECP concentration in the sample 
(20). The concentration of NT-proBNP was determined us-
ing electrochemiluminiescence immunoassay on Cobas 
e411 analyzer (Roche Diagnostics GmbH, Mannheim, Ger-
many) (21). The method principle is a sandwich principle 
where antigen in the sample, biotinylated monoclonal anti-
NT-proBNP specific antibody, and a monoclonal NT-proB-
NP-specific antibody labeled with ruthenium complex re-
act and form a sandwich complex. Afterwards, the complex 
bounds to streptavidin-coated microparticles, which are 
magnetically captured onto the surface of the electrode. 
Application of voltage to the electrode induces chemilumi-
niscent emission, which is measured by a photomultiplier.
The concentration of hsCRP was determined using im-
munoturbidimetric method on AU 2700 plus analyzer 
(Beckman-Coulter, Tokyo, Japan). In brief, CRP reacts with 
antibodies to human CRP latex particles, forming insolu-
ble aggregates. The absorption of generated aggregates 
is proportional to the concentration of CRP in the sample. 
The method was calibrated with Latex CRP Calibrator Set 
High Sensitive (ODCO27) with five different calibrator con-
centrations for low sensitive area (22).
Creatinine, total cholesterol, albumin, iron, and UIBC were 
determined on AU 2700 plus analyzer (Beckman-Coulter). 
Creatinine and total cholesterol were determined using 
enzymatic color tests. Albumin, iron, and UIBC were deter-
mined using photometric color tests.
Statistical analysis
The study population was divided into two groups accord-
ing to the median of red cell distribution width (RDW) in 
order to facilitate the clinical application of our results. A 
similar study design was used in previously published 
studies (10,16). All variables were tested for normal distri-
bution by the Kolmogorov-Smirnov test. Summary statis-
tics for the continuous variables were presented as mean± 
SD or median with range, and comparisons between the 
two groups were preformed with the Mann-Whitney U 
test. Categorical data were expressed as number (N), and 
comparisons between categorical data in Table 1 were 
preformed with χ2 test. Correlations between RDW and 
other continuous variables were tested using Pearson test 
or the Spearman correlation, as appropriate. Kaplan-Meier 
survival curves were drawn and Log-rank values were cal-
culated to assess their statistical significance. Prognostic 
variables for mortality were analyzed by using the univari-
ate Cox proportional hazards model, and variables with P-
value <0.1 in univariate analysis were used in the stepwise 
multivariate Cox proportional hazards model. The univari-
ate and multivariate Cox regression analysis results are pre-
sented as hazard ratios (HR) and 95% confidence intervals. 
The discrimination of RDW for one-year all-cause mortality 
was evaluated using the area under the receiver operat-
ing characteristic (ROC) curve. In addition, we divided the 
patients into grade 1 or 2 group depending on RDW value 
(RDW group 1 consisted of patients who had RDW below 
the median RDW and RDW group 2 consisted of patients 
who had RDW above the median RDW). RDW group 1 was 
given score 1 and RDW group 2 was given score 2, and 
the score was subsequently added to baseline ECOG score. 
AUC was calculated for RDW levels, ECOG score, and ECOG 
score plus graded RDW score. The optimal cut off point for 
ROC curves was selected for maximizing the sensitivity and 
specificity of the selected values. P-value of <0.05 was con-
sidered statistically significant. MedCalc, version 11.4.2.0 
(Ostend, Belgium) and JMP, version 9.0.2 software (Cary, 
NC, USA) were used.
ReSuLtS
Population characteristics
The study population consisted of 100 patients who 
were stratified at the time of inclusion by median RDW of 
15.75 (Table 1). Patients with an elevated RDW had high-
er incidence of stroke/TIA (P = 0.0371), but there were no 
significant differences between the groups in other vari-
ables. Fifty two patients were men and the median age 
of all patients was 72 years (interquartile range 28-93). 
RDW ranged from 13.2 to 19.7; with a mean value of 
15.9 ± 1.4.
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Association between RdW values and other parameters
There were no significant correlations between RDW and 
RBC indices, such as hemoglobin and MCV (r = -0.0896, 
P = 0.375; r = 0.0491, P = 0.627). Correlation between RDW 
and serum albumin, atrial fibrillation, stroke history, serum 
iron, and beta-blocker usage was significant but marginal 
(r = -0.282, P = 0.038; r = 0.208, P = 0.038; r = 0.227, P = 0.023, 
r = -0.240, P = 0.016, respectively). We found no correlations 
between RDW and WBC, total cholesterol, serum creati-
nine, serum ECP, hs-CRP, TIBC, KT/V, ECOG status, and IMT.
Survival vs non-survival group
A total of 25 patients died during the follow-up period of 
one-year. At inclusion time, patients who died had signifi-
cantly higher RDW levels (16.7% [14.3-19.5] vs 15.5% [13.2-
19.7], P < 0.001, Figure 1) and lower hemoglobin levels (107 
[61-138] vs 115 [65-138], P = 0.048). They also had significant-
ly higher ECOG class (4 [2-4] vs 2 [1-4], P < 0.001), increased 
IMT (0.71 [0.47-1.25] vs 0.63 [0.31-1.55], P = 0.011), increased 
nt-pro-BNP concentrations (8300 [1108-35000] vs 4837 [413-
35000],PP = 0.043), and increased C-reactive protein concen-
trations (11.6 [1.3-154.2] vs 4.9 [0.4-92.9], P < 0.001).
Risk analysis for all-cause mortality
For each 1% point increase in RDW value as a continuous 
variable, one-year all cause mortality risk was increased by 
54% in univariate Cox proportional hazard analysis. In multi-
variate Cox proportional hazard model, in order to examine 
independent nature of RDW in prediction of all-cause mor-
tality an adjustment for known co-morbidities and potent 
predictors was made. In the final calculation, a prognostic 
tABLe 1. Baseline characteristics (demographics, history, clinical and laboratory parameters) of patients on hemodialysis, divided 
according to red blood cell distribution width (RdW) (median)
Variable RdW≤15.75 (n = 50) RdW>15.75 (n = 50) P*
Age (years), mean±SD† 66.4 ± 14.2 67.7 ± 14 0.484
Male sex, N 23 29 0.926
Body mass index (kg/m2), mean±SD 25.9 ± 4.8 25.5 ± 5.3 0.539
History of arterial hypertension, N 41 44 0.416
History of diabetes mellitus, N 14 21 0.148
History of coronary artery disease, N 14 10 0.3595
History of stroke/ transitory ischemic attack, N 1 7 0.037
Erythropoietin therapy, N 46 44 0.525
Duration of dialysis (months), median (range) 36 (6-180) 29 (6-360) 0.390
Kt/V, mean±SD 1.37 ± 0.21 1.3 ± 0.24 0.068
Eastern Cooperative Oncology Group performance status, median (range) 2 (1-4) 2.5 (1-4) 0.105
Atrial fibrillation, N 7 14 0.093
Carotid intima-media thickness (mm), mean±SD 0.65 ± 0.17 0.71 ± 0.20 0.148
ACE/AT II blockers at presentation, N 18 20 0.685
Beta-blocker at presentation, N 17 19 0.681
Calcium-blocker at presentation, N 23 32 0.074
Statins at presentation, N 12 17 0.279
Proton pump inhibitor at presentation, N 12 19 0.137
White blood cells (cells ×109/L), mean±SD 7.02 ± 2.04 7.08 ± 1.93 0.796
Hemoglobin (g/L), mean±SD 114 ± 15 109 ± 17 0.196
Mean corpuscular volume (fL), mean±SD 96 ± 4 96 ± 6 0.890
Creatinin (mmol/L), mean±SD 825 ± 196 809 ± 254 0.590
hs-C-reactive protein (mg/L), median (range) 5.725 (0.6-92.9) 7.850 (0.4-154.2) 0.125
nt-pro-brain natriuretic peptide (pg/mL), median (range) 4671 (413-35000) 6633 (466-35000) 0.131
Serum albumin (g/L), mean±SD 38 ± 3 36 ± 4 0.147
Total cholesterol (mmol/L), mean±SD 4.33 ± 1.01 4.45 ± 1.34 0.920
Iron (µmol/L), mean±SD 12.6 ± 4.5 11.6 ± 5.1 0.359
Total iron binding capacity (µmol/L), mean±SD 35.1 ± 5.6 34.8 ± 7.9 0.793
Eosinophilic cationic protein (µg/L), mean±SD 15.69 ± 10.06 18.33 ± 17.26 0.912
*Mann-Whitney test was predominately used, except for calculation of difference in sex, wher χ2 test was used. P < 0.05 is considered as significant.
†Sd – standard deviation.
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value of RDW was strong and independent (HR 1.5346, 95% 
CI, 1.1607 to 2.0290, P = 0.002), even after adjustment for co 
morbidities and previously known significant predictors for 
all-cause mortality at one year (Table 2). In the final model, 
when RDW was entered as categorized variable according 
to the median value of the study group, mortality risk was 
significantly increased (HR 5.15, 95% CI 2.33 to 11.36) and pa-
tients with RDW value above 15.75% had significantly lower 
survival time (Log rank P < 0.001) (Figure 2).
The ROC curves using variables (RDW value, ECOG value, 
and ECOG value plus graded RDW score) are plotted in 
Figure 3. The area under the curve (AUC) of RDW value 
alone for one-year all-cause mortality was 0.745 (95% CI 
0.648 to 0.827; optimal cut-off value at 15.5% with sensi-
tivity 88.0% and specificity 54.6%, P < 0.001) and of ECOG 
status 0.834 (95% CI 0.746 to 0.901; optimal cut-off value 
at 2 with sensitivity 80.0% and specificity 68.0%, P < 0.001). 
In a pair-wise comparison of ROC curves, there was no 
significant difference between AUC of RDW and ECOG 
(95% CI -0.0496 to 0.228, P = 0.207), but adding graded 
RDW to ECOG status significantly improved prognostic 
performance of the RDW alone model (AUC 0.872, 95% CI 
0.0176 to 0.237, P = 0.022).
tABLe 2. Cox proportional hazards analysis for all-cause mortality at 12 months
univariate Multivariate
hazard ratio 
(95% confidence 
interval)
P 
(Cox proportional 
hazard analysis)
hazard ratio 
(95% confidence 
interval)
P 
(Cox proportional 
hazard analysis)
Age, years 1.0560 (1.0190-1.0945) <0.001 NS*
Eastern Cooperative Oncology Group 
performance status
3.5347 (2.1569-5.7927) <0.001 3.8624 (2.2769-6.5521) <0.001
Kt/V 0.0454 (0.0065-0.3177) <0.001 0.0189 (0.0023-0.1580) <0.001
Atrial fibrillation 0.2640 (0.1201-0.5804) <0.001 NS
Carotid intima-media thickness 21.2398 (2.9253-154.2142) 0.004 NS
Diabetes mellitus 2.2056 (1.0100-4.8165) 0.049 NS
Hemoglobin 0.9734 (0.9522-0.9951) 0.022 NS
Highly sensitive C-reactive protein 1.0177 (1.0076-1.0278) 0.005 1.0255 (1.0119-1.0392) <0.001
NT-pro-brain natriuretic peptide 1 (1.0000-1.0001) 0.019 NS
Eosinophil cationic protein 1.0322 (1.0005-1.0648) 0.049 NS
Red cell distribution width 1.5409 (1.2181-1.9493) <0.001 1.5346 (1.1607-2.0290) 0.002
*NS – not included in multivariate model due to limitations made by used statistic model.
FiguRe 1. Red blood cell distribution width (RdW) measures 
as a function of mortality at one year of follow-up (data 
presented as median of RdW with 95% confidence interval for 
median).
FiguRe 2. Kaplan-Meier survival curves according to red blood 
cell distribution width (RdW) values above or below the RdW 
median (15.75%).
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diSCuSSioN
Our study indicated that RDW value was an independent 
predictor of all-cause mortality in patients on chronic di-
alysis. This finding remained significant even in the pres-
ence of other powerful prognostic biomarkers such as NT-
proBNP, hsCRP, or IMT, which are all validated prognostic 
parameters in chronic dialysis (23-25). When we divided 
patients into two groups according to the RDW median 
of 15.75%, the survival rate was significantly lower in the 
higher RDW group, but there were no significant differenc-
es between the groups in the tested variables except for 
stroke/TIA incidence. There was also an independent and 
additive effect of RDW in the assessment of survival in pa-
tients on chronic dialysis. Previous studies in general popu-
lation and specific subgroups of patients found significant 
correlation between RDW and hemoglobin concentration, 
MCV, hsCRP, and WBC (7,10,25), while our study found no 
significant correlation between RDW and RBC indices, 
suggesting that pathogenesis of elevated RDW in pa-
tients on chronic dialysis was even more complex 
than in general population. In some studies performed on 
patients on dialysis, it was shown that RDW was associated 
with iron deficiency status (26), but our study showed RDW 
value to be independent of iron status.
An interesting finding was an increased incidence of stroke/
TIA in the group with higher RDW. Similarly, Ani et al found 
that elevated RDW was associated with stroke occurrence 
and strongly predicted both cardiovascular and all-cause 
deaths in persons with known stroke (27), which could 
all indicate a possible role of RDW in the increased risk of 
cerebrovascular thrombosis (26,28). Our data on this sub-
ject are limited, and a specific study should be designed to 
test this finding. Although one could suspect that RDW is 
primary connected with atherosclerosis, or with ECP, which 
was presented as biomarker of coronary atherosclerosis, 
our results do not implicate that this biomarker is relevant 
for RDW values, suggesting a pathogenic pathway differ-
ent from those of ECP (5).
ECOG score has been commonly used for years in patients 
with malignancy (18), but it can be applied for accurate as-
sessment of daily living abilities in every patient. When we 
added graded RDW score to ECOG score, we significant-
ly improved prognostic performance of the RDW alone 
model. Combining a simple clinical assessment tool, such 
as ECOG score, with RDW resulted in a very reliable prog-
nostic tool, which can be applicable among patients in 
chronic dialysis in everyday clinical practice. These results 
are in line with those of Hunziker et al (14), who have prov-
en that adding RDW to SAPS prognostic tool significantly 
improves prognostic reliability of SAPS score in identifying 
critically ill patients.
Correlation between RDW and albumin, atrial fibrillation, 
stroke history, and iron and beta-blocker usage was sig-
nificant but marginal. A negative significant correlation of 
RDW with albumin and atrial fibrillation could be explained 
by a more frequent occurrence of both hypoalbuminemia 
and atrial fibrillation in patients who are in the chronic 
state of malnutrition (16). It has already been hypothesized 
that malnutrition could be one of the causes of increased 
RDW in patients on chronic dialysis (29).
Little is known about the mechanism by which elevat-
ed values of RDW are associated with increased mortality. 
Usually, RDW is elevated when there is increased red cell 
destruction, or what is more common, ineffective and in-
creased red cell production, which are both prevalent in 
patients on dialysis (29). RDW may represent malnutrition, 
FiguRe 3. Additive prognostic value of red blood cell distribu-
tion width (RdW) in patients on chronic dialysis measured 
by comparison of area under the receiver operating charac-
teristic curve (AuC) for 1) RdW alone, 2) eastern Cooperative 
oncology group performance (eCog) alone, and 3) eCog plus 
graded RdW score.
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suppression of bone marrow production, or chronic in-
flammation (16). Although the mainstay of atherosclerosis 
pathogenesis and progression is chronic inflammation, it 
is highly unlikely that the relation of RDW to mortality risk 
is based only on the premise of chronic inflammation. Fur-
thermore, it has been shown that the risk associated with 
RDW was not significantly diminished in participants with a 
low CRP compared with those with a high CRP level (14,16). 
Therefore, a final theory is based on oxidative stress associa-
tion with RDW (14). Oxidative stress has been shown to in-
crease anisocytosis by disrupting erythropoiesis and to alter 
blood cell membrane deformability and red blood cell cir-
culation half-life, ultimately leading to increased RDW (14). 
The proposed mechanism includes ischemia and oxida-
tive stress as a driving force that activates cellular systems 
that would reduce oxygen demand and physiologic pro-
cesses that would improve tissue oxygen delivery, such as 
increased production and release of mature red cells into 
the peripheral bloodstream. Release of large immature red 
cells with poor oxygen-binding capacity, which results in 
an increased RDW, implies suboptimal response to oxida-
tive stress. This has been offered as an explanation why the 
association between RDW and clinical outcome is indepen-
dent of the severity of acute illness as well as the degree of 
inflammation (14). This hypothesis requires further investi-
gation, but it seems that it could be also applied to our pa-
tient group. Whatever the reason may be, all of these con-
ditions are common in patients on hemodialysis and are 
associated with unfavorable prognosis (30). Association of 
RDW with all-cause mortality indicates that not only deaths 
from cardiovascular diseases, but cancer and other causes 
are all connected to RDW, which is also supported by find-
ings of a meta-analysis on older populations (8)
This study has several limitations. We did not evaluate 
fluctuations in RDW values and thus could not account 
for possible variation over time. Also, regardless of the 
prospective longitudinal design of the study, one year is 
a rather short follow-up and we would suggest a larger, 
multicenter study with longer follow-up to make definitive 
conclusions and evaluate our findings. Despite these limi-
tations, a major strength of this study lies in its prospec-
tive design with good follow-up and low drop-out. What is 
more important, this study is based on real-life “every day 
dialysis patient” sample.
In conclusion, our study demonstrated that RDW could 
be an additive predictor for all-cause mortality in patients 
on chronic dialysis. Available literature data do not pro-
vide clear explanations for such a finding, but nevertheless 
RDW combined with sound clinical judgment, ie, ECOG 
score improves identification of patients with an increased 
risk compared to RDW model alone. Since RDW is a simple, 
inexpensive, and widely available test, these data may have 
significant clinical implications for assessing prognosis and 
choice of treatment in patients on chronic dialysis.
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